Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1043 in Healthy Adults With Overweight or Obesity
NCT07511205Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of AZD1043 in obesity (13 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events (AEs), serious adverse events (SAEs), AE leading to discontinuation (DAEs), and AEs of special interest (AESIs). Started Mar 2026; status: recruiting.
02
Drugs
AZD1043
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07511205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511205.